{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:50:16Z","timestamp":1761648616683},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer S.L.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12944-018-0918-y","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T18:28:33Z","timestamp":1544120913000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"A.","family":"Sicras-Mainar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"S\u00e1nchez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Navarro-Artieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Darb\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"issue":"1","key":"918_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","volume":"17","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"918_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.medcli.2013.01.015","volume":"141","author":"A Salinas Botr\u00e1n","year":"2013","unstructured":"Salinas Botr\u00e1n A, Ramos Rinc\u00f3n JM, de G\u00f3rgolas Hern\u00e1ndez-Mora M. Cardiovascular disease: a view from global health perspective. Med Clin (Barc). 2013;141(5):210\u20136.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"918_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.recesp.2016.11.052","volume":"70","author":"AL Catapano","year":"2017","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the Management of Dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Rev Esp Cardiol (Engl Ed). 2017;70(2):72\u20137.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"4","key":"918_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.rce.2013.12.014","volume":"214","author":"R G\u00f3mez-Huelgas","year":"2014","unstructured":"G\u00f3mez-Huelgas R, P\u00e9rez-Jim\u00e9nez F, Serrano-R\u00edos M, Gonz\u00e1lez-Santos P, Rom\u00e1n P, Camafort M, et al. SEMI working group; Spanish Society of Internal Medicine. Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine. Rev Clin Esp (Barc). 2014;214(4):209\u201315.","journal-title":"Rev Clin Esp (Barc)"},{"issue":"11","key":"918_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","volume":"32","author":"TJ Anderson","year":"2016","unstructured":"Anderson TJ, Gr\u00e9goire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263\u201382.","journal-title":"Can J Cardiol"},{"issue":"19","key":"918_CR6","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","volume":"316","author":"K Bibbins-Domingo","year":"2016","unstructured":"US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316(19):1997\u20132007.","journal-title":"JAMA"},{"issue":"4","key":"918_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40263-017-0420-5","volume":"31","author":"T Xu","year":"2017","unstructured":"Xu T, Yu X, Ou S, Liu X, Yuan J, Chen Y. Statin adherence and the risk of stroke: a dose-response meta-analysis. CNS Drugs. 2017;31(4):263\u201371.","journal-title":"CNS Drugs"},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","volume":"225","author":"M Banach","year":"2016","unstructured":"Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184\u201396.","journal-title":"Int J Cardiol"},{"issue":"40","key":"918_CR9","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.2174\/1381612820666140620162629","volume":"20","author":"K Phan","year":"2014","unstructured":"Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr Pharm Des. 2014;20(40):6314\u201324.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"918_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11886-011-0221-2","volume":"13","author":"A Mauskop","year":"2011","unstructured":"Mauskop A, Borden WB. Predictors of statin adherence. Curr Cardiol Rep. 2011;13(6):553\u20138.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"918_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","volume":"15","author":"B Davit","year":"2013","unstructured":"Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974\u201390.","journal-title":"AAPS J"},{"issue":"5","key":"918_CR12","first-page":"923","volume":"70","author":"J Maly","year":"2013","unstructured":"Maly J, Dosedel M, Kubena A, Vlcek J. Analysis of pharmacists\u2019 opinions, attitudes and experiences with generic drugs and generic substitution in the Czech Republic. Acta Pol Pharm. 2013;70(5):923\u201331.","journal-title":"Acta Pol Pharm"},{"issue":"3","key":"918_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.gaceta.2009.12.003","volume":"24","author":"J Puig-Junoy","year":"2010","unstructured":"Puig-Junoy J. Policies encouraging price competition in the generic drug market: lessons from the European experience. Gac Sanit. 2010;24(3):193\u20139.","journal-title":"Gac Sanit"},{"issue":"4","key":"918_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","volume":"31","author":"L Manzoli","year":"2016","unstructured":"Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351\u201368.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"918_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pharep.2015.08.017","volume":"68","author":"G Cessak","year":"2016","unstructured":"Cessak G, Rokita K, D\u0105browska M, Sejbuk-Rozbicka K, Zaremba A, Mirowska-Guzel D, et al. Therapeutic equivalence of antipsychotics and antidepressants - a systematic review. Pharmacol Rep. 2016;68(2):217\u201323.","journal-title":"Pharmacol Rep"},{"issue":"6","key":"918_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.gaceta.2010.07.007","volume":"24","author":"A Sicras-Mainar","year":"2010","unstructured":"Sicras-Mainar A, Navarro-Artieda R. Influencia de la sustituci\u00f3n de medicamentos de marca por gen\u00e9ricos en el cumplimiento terap\u00e9utico de la hipertensi\u00f3n arterial y dislipemia. Gac Sanit. 2010;24(6):473\u201382.","journal-title":"Gac Sanit"},{"issue":"3","key":"918_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4103\/0976-500X.99438","volume":"3","author":"A Sicras-Mainar","year":"2012","unstructured":"Sicras-Mainar A, Navarro-Artieda R. Physicians\u2019 and patients\u2019 opinions on the use of generic drugs. J Pharmacol Pharmacother. 2012;3(3):268\u201370.","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"918_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7326\/M14-2427","volume":"164","author":"NK Choudhry","year":"2016","unstructured":"Choudhry NK, Denberg TD, Qaseem A. Clinical guidelines Committee of American College of physicians. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the clinical guidelines Committee of the American College of physicians. Ann Intern Med. 2016;164(1):41\u20139.","journal-title":"Ann Intern Med"},{"issue":"3","key":"918_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012586","volume":"7","author":"B Lumbreras","year":"2017","unstructured":"Lumbreras B, L\u00f3pez-Pintor E. Impact of changes in pill appearance in the adherence to angiotensin receptor blockers and in the blood pressure levels: a retrospective cohort study. BMJ Open. 2017;7(3):e012586.","journal-title":"BMJ Open"},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1186\/s12913-014-0626-x","volume":"14","author":"H Trusell","year":"2014","unstructured":"Trusell H, Sundell KA. Effects of generic substitution on refill adherence to statin therapy: a nationwide population-based study. BMC Health Serv Res. 2014;14:626.","journal-title":"BMC Health Serv Res"},{"key":"918_CR21","volume-title":"The international classification of primary Care in the European Community. With a multi-language layer","author":"H Lamberts","year":"1993","unstructured":"Lamberts H, Wood M, Hofmans-Okkes \u00cdM. The international classification of primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press; 1993."},{"key":"918_CR22","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization. Available from: \n                    http:\/\/www.who.int\/classifications \/atcddd\/en\/\n                    \n                   [cited: 10th July 2017]."},{"issue":"5","key":"918_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"2","key":"918_CR24","first-page":"308","volume":"30","author":"A Sicras-Mainar","year":"2013","unstructured":"Sicras-Mainar A, Navarro-Artieda R. Adjusted clinicals groups: a patient classification system through risk adjustment. Rev Peru Med Exp Salud Publica. 2013;30(2):308\u201314.","journal-title":"Rev Peru Med Exp Salud Publica"},{"key":"918_CR25","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Observatorio de uso de medicamentos. Utilizaci\u00f3n de medicamentos hipolipemiantes en Espa\u00f1a durante el periodo 2000\u20132012. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios; 2013. Available from: \n                    http:\/\/aemps.gov.es\/home.htm\n                    \n                  . [cited: August 2017]"},{"issue":"4","key":"918_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455\u201361.","journal-title":"JAMA"},{"key":"918_CR27","unstructured":"Instituto Nacional de Estad\u00edstica 2013. Encuesta de costes laborales del a\u00f1o 2013. Available from: \n                    http:\/\/ine.es\n                    \n                  . [cited: July 2017]."},{"issue":"8","key":"918_CR28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","volume":"12","author":"ML Berger","year":"2009","unstructured":"Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report--part I. Value Health. 2009;12(8):1044\u201352.","journal-title":"Value Health"},{"issue":"5","key":"918_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison Jr","year":"2007","unstructured":"Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326\u201335.","journal-title":"Value Health"},{"issue":"2","key":"918_CR30","first-page":"e1","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;16(2):e1\u20135.","journal-title":"BMJ"},{"key":"918_CR31","doi-asserted-by":"crossref","unstructured":"Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R, et al. Impact of substitution among generic drugs on persistence and adherence: a retrospective claims data study from 2 local healthcare units in the Lombardy region of Italy. Atheroscler Suppl. 2016;21(1\u20138).","DOI":"10.1016\/j.atherosclerosissup.2016.02.001"},{"issue":"6","key":"918_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.gaceta.2010.07.007","volume":"24","author":"A Sicras Mainar","year":"2010","unstructured":"Sicras Mainar A, Navarro Artieda R. Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia. Gac Sanit. 2010;24(6):473\u201382.","journal-title":"Gac Sanit"},{"key":"918_CR33","first-page":"299","volume":"7","author":"A Sicras-Mainar","year":"2015","unstructured":"Sicras-Mainar A, Rejas-Guti\u00e9rrez J, Navarro-Artieda R. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. Clinicoecon Outcomes Res. 2015;7:299\u2013312.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"918_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.7326\/M13-2381","volume":"161","author":"AS Kesselheim","year":"2014","unstructured":"Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014;161(2):96\u2013103.","journal-title":"Ann Intern Med"},{"issue":"12","key":"918_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1525-1497.2001.10412.x","volume":"16","author":"MA Steinman","year":"2001","unstructured":"Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16(12):793\u20139.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"918_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.nrl.2016.03.012","volume":"33","author":"R Navarro-Artieda","year":"2018","unstructured":"Navarro-Artieda R, Rejas-Guti\u00e9rrez J, P\u00e9rez-Paramo M, Sicras-Mainar A. Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: the effects of age and sex. Neurologia. 2018;33(3):141\u201353.","journal-title":"Neurologia"},{"issue":"2","key":"918_CR37","first-page":"e205","volume":"14","author":"YB Tran","year":"2007","unstructured":"Tran YB, Frial T, Miller PS. Statin\u2019s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2007;14(2):e205\u201314.","journal-title":"Can J Clin Pharmacol"},{"issue":"6","key":"918_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7326\/M13-2942","volume":"161","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400\u20137.","journal-title":"Ann Intern Med"},{"issue":"5","key":"918_CR39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","volume":"70","author":"AS Kesselheim","year":"2010","unstructured":"Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70(5):605\u201321.","journal-title":"Drugs"},{"issue":"4","key":"918_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","volume":"31","author":"L Manzoli","year":"2016","unstructured":"Manzoli L, Flacco ME, Boccia S, D\u2019Andrea E, Panic N, Marzuillo C, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351\u201368.","journal-title":"Eur J Epidemiol"},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40780-015-0013-8","volume":"1","author":"Y Mano","year":"2015","unstructured":"Mano Y, Fukushima S, Kuroda H, Ohshima H, Kato Y, Ohuchi K, et al. Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims. J Pharm Health Care Sci. 2015;1:12.","journal-title":"J Pharm Health Care Sci"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13104-017-2617-6","volume":"10","author":"A Loch","year":"2017","unstructured":"Loch A, Bewersdorf JP, Kofink D, Ismail D, Abidin IZ, Veriah RS. Generic atorvastatin is as effective as the brand-name drug (LIPITOR) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Res Notes. 2017;10:291.","journal-title":"BMC Res Notes"},{"issue":"2","key":"918_CR43","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1097\/MJT.0000000000000098","volume":"23","author":"KD Candido","year":"2016","unstructured":"Candido KD, Chiweshe J, Anantamongkol U, Knezevic NN. Can chronic pain patients be adequately treated using generic pain medications to the exclusion of brand-name ones? Am J Ther. 2016;23(2):e489\u201397.","journal-title":"Am J Ther"},{"key":"918_CR44","first-page":"288","volume":"21","author":"J Fraeyman","year":"2015","unstructured":"Fraeyman J, Peeters L, Van Hal G, Beutels P, De Meyer GR, De Loof H. Consumer choice between common generic and brand medicines in a country with a small generic market. J Manag Care Spec Pharm. 2015;21:288\u201396.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-018-0918-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:06:08Z","timestamp":1575590768000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-018-0918-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1186\/s12944-018-0918-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"20 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors state that the manuscript is based in an investigation classified by the Spanish Agency for Medicines and Medical Devices (AEMPS) as a Post-Authorisation Study - Other Design (EPA-OD), and subsequently was approved by the Institutional Research Board of the Universitat Internacional de Catalunya in Barcelona (Code: ANT-HIP-2017-01) on September, 7th, 2017. Patient consent was not obtained as Spanish legislation excludes existing data that are aggregated for analysis and personal data are stripped of identifying details as specified in Spanish Law 15\/1999, of 13 December, on Personal Data Protection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Antoni Sicras-Mainar is an employee of ClinicResearch. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"277"}}